Roger Paredes, MD, PhD
Roger Paredes, MD, PhD
Infectious Diseases Department & irsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol
Verified email at irsicaixa.es
Title
Cited by
Cited by
Year
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
11752011
Remdesivir for the treatment of Covid-19—preliminary report
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine, 2020
8172020
2015 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Top Antivir Med 23 (4), 132-41, 2015
6762015
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
676*2014
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
676*2014
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460-465, 2010
5782010
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
3802011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ...
Jama 305 (13), 1327-1335, 2011
3492011
Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ...
Journal of acquired immune deficiency syndromes (1999) 25 (3), 221-228, 2000
3232000
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population
AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ...
Aids 27 (6), 973-979, 2013
3202013
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
3022013
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study
R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ...
Archives of internal medicine 160 (8), 1123-1132, 2000
2842000
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
AMN Tsibris, B Korber, R Arnaout, C Russ, CC Lo, T Leitner, B Gaschen, ...
PloS one 4 (5), e5683, 2009
2382009
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ...
Aids 14 (4), 397-403, 2000
2332000
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
R Paredes, CM Lalama, HJ Ribaudo, BR Schackman, C Shikuma, ...
The Journal of infectious diseases 201 (5), 662-671, 2010
2162010
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and …
E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, ...
Clinical infectious diseases 34 (4), 504-510, 2002
2122002
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a …
L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ...
Journal of acquired immune deficiency syndromes (1999) 27 (3), 229-236, 2001
2042001
Gut microbiota linked to sexual preference and HIV infection
M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ...
EBioMedicine 5, 135-146, 2016
1892016
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
CR Fumaz, A Tuldra, MJ Ferrer, R Paredes, A Bonjoch, T Jou, E Negredo, ...
JAIDS-HAGERSTOWN MD- 29 (3), 244-253, 2002
1782002
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
L Ruiz, G Carcelain, J Martínez-Picado, S Frost, S Marfil, R Paredes, ...
Aids 15 (9), F19-F27, 2001
1772001
The system can't perform the operation now. Try again later.
Articles 1–20